GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
Income from Continuing Operations
GlaxoSmithKline Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
|
Income from Continuing Operations
₹8.6B
|
CAGR 3-Years
31%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹54.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹50B
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹114.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹18.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Income from Continuing Operations
₹19.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline Pharmaceuticals Ltd
Glance View
GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.
See Also
What is GlaxoSmithKline Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
8.6B
INR
Based on the financial report for Dec 31, 2024, GlaxoSmithKline Pharmaceuticals Ltd's Income from Continuing Operations amounts to 8.6B INR.
What is GlaxoSmithKline Pharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
49%
Over the last year, the Income from Continuing Operations growth was 62%. The average annual Income from Continuing Operations growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been 31% over the past three years , 49% over the past five years .
You don't have any saved screeners yet